• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists.

作者信息

Drillet Gaëlle, Lhomme Faustine, De Guibert Sophie, Manson Guillaume, Houot Roch

机构信息

Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.

INSERM U1236, Rennes, France.

出版信息

Blood Adv. 2023 Feb 28;7(4):537-540. doi: 10.1182/bloodadvances.2022008066.

DOI:10.1182/bloodadvances.2022008066
PMID:35930692
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9979763/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fca8/9979763/b14def9a5c45/BLOODA_ADV-2022-008066-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fca8/9979763/b14def9a5c45/BLOODA_ADV-2022-008066-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fca8/9979763/b14def9a5c45/BLOODA_ADV-2022-008066-gr1.jpg

相似文献

1
Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists.CAR-T细胞疗法后出现的持续性血小板减少症：血小板生成素受体激动剂的作用
Blood Adv. 2023 Feb 28;7(4):537-540. doi: 10.1182/bloodadvances.2022008066.
2
Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.病程小于6个月的免疫性血小板减少症中的血小板生成素受体激动剂
Intern Med J. 2014 May;44(5):519-21. doi: 10.1111/imj.12406.
3
Thrombopoietin receptor agonists in adult Evans syndrome: an international multicenter experience.成人Evans综合征中血小板生成素受体激动剂：一项国际多中心经验
Blood. 2022 Aug 18;140(7):789-792. doi: 10.1182/blood.2022016818.
4
Thrombopoietin receptor agonists: a new immune modulatory strategy in immune thrombocytopenia?血小板生成素受体激动剂：免疫性血小板减少症中的一种新的免疫调节策略？
Semin Hematol. 2016 Apr;53 Suppl 1:S31-4. doi: 10.1053/j.seminhematol.2016.04.010. Epub 2016 Apr 7.
5
[Management of refractory ITP with thrombopoietin receptor agonists].[血小板生成素受体激动剂治疗难治性免疫性血小板减少症]
Rinsho Ketsueki. 2011 Aug;52(8):627-32.
6
[Development of thrombopoietin receptor agonists].[血小板生成素受体激动剂的研发]
Rinsho Ketsueki. 2009 Oct;50(10):1434-43.
7
Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.超越免疫性血小板减少症：血小板生成素受体激动剂不断演变的作用
Ann Hematol. 2017 Sep;96(9):1421-1434. doi: 10.1007/s00277-017-2953-6. Epub 2017 Mar 8.
8
Immune thrombocytopenic purpura--from agony to agonist.免疫性血小板减少性紫癜——从痛苦到激动剂
N Engl J Med. 2007 Nov 29;357(22):2299-301. doi: 10.1056/NEJMe0707126.
9
Thrombopoietin-receptor agonists in children with immune thrombocytopenia.免疫性血小板减少症患儿的血小板生成素受体激动剂
Lancet. 2015 Oct 24;386(10004):1606-9. doi: 10.1016/S0140-6736(15)61223-5. Epub 2015 Jul 28.
10
What's new in the management of chronic primary immune thrombocytopenia in adults and the use of thrombopoietin receptor agonists.成人慢性原发性免疫性血小板减少症的管理及血小板生成素受体激动剂的应用有哪些新进展？
Med Princ Pract. 2011;20(4):301-2. doi: 10.1159/000324876. Epub 2011 May 11.

引用本文的文献

1
Platelet Transfusion for Patients with Cancer: An Update.癌症患者的血小板输注：最新进展
Transfus Med Hemother. 2025 Jun 12. doi: 10.1159/000546566.
2
Pharmacovigilance in Cell and Gene Therapy: Evolving Challenges in Risk Management and Long-Term Follow-Up.细胞与基因治疗中的药物警戒：风险管理与长期随访中不断演变的挑战
Drug Saf. 2025 Aug 9. doi: 10.1007/s40264-025-01596-9.
3
Noncanonical and mortality-defining toxicities of CAR T cell therapy.嵌合抗原受体T细胞疗法的非典型及决定死亡率的毒性作用

本文引用的文献

1
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.依鲁替尼联合免疫抑制治疗重型再生障碍性贫血。
N Engl J Med. 2022 Jan 6;386(1):11-23. doi: 10.1056/NEJMoa2109965.
2
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.嵌合抗原受体 T 细胞相关血液学毒性：复发/难治性大 B 细胞淋巴瘤中嵌合抗原受体 T 细胞相关血液学毒性的模型。
Blood. 2021 Dec 16;138(24):2499-2513. doi: 10.1182/blood.2020010543.
3
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma.
Nat Med. 2025 Jul 16. doi: 10.1038/s41591-025-03813-5.
4
Toxicities Associated with CAR-T Cell Therapies.与嵌合抗原受体T细胞疗法相关的毒性
Mediterr J Hematol Infect Dis. 2025 May 1;17(1):e2025039. doi: 10.4084/MJHID.2025.039. eCollection 2025.
5
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS.多发性骨髓瘤中的T细胞重定向疗法：细胞因子释放综合征和免疫效应细胞相关神经毒性综合征之外的发病机制及毒性管理
Cancers (Basel). 2025 Apr 30;17(9):1514. doi: 10.3390/cancers17091514.
6
Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies.免疫效应细胞相关的血液毒性：机制、临床表现及管理策略。
Haematologica. 2025 Jun 1;110(6):1254-1268. doi: 10.3324/haematol.2024.286027. Epub 2025 Feb 20.
7
New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies.嵌合抗原受体T细胞血液学毒性的新见解：表现、机制及有效管理策略
Exp Hematol Oncol. 2024 Nov 9;13(1):110. doi: 10.1186/s40164-024-00573-9.
8
Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients.使用艾曲泊帕改善抗CD19嵌合抗原受体T细胞治疗患者的血小板减少症及输血需求
J Clin Med. 2024 Aug 28;13(17):5117. doi: 10.3390/jcm13175117.
9
Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.抗CD19嵌合抗原受体T细胞疗法治疗复发/难治性B细胞非霍奇金淋巴瘤后的晚期事件
Front Oncol. 2024 Jun 11;14:1404351. doi: 10.3389/fonc.2024.1404351. eCollection 2024.
10
CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations.嵌合抗原受体 T 细胞毒性：从床边到实验室，新型毒性如何为实验室研究提供信息。
Blood Adv. 2024 Aug 27;8(16):4348-4358. doi: 10.1182/bloodadvances.2024013044.
在复发或难治性大 B 细胞淋巴瘤中使用 axicabtagene ciloleucel 后的免疫重建和相关感染。
Haematologica. 2021 Apr 1;106(4):978-986. doi: 10.3324/haematol.2019.238634.
4
Thrombopoietin receptor agonists: ten years later.血小板生成素受体激动剂：十年后。
Haematologica. 2019 Jun;104(6):1112-1123. doi: 10.3324/haematol.2018.212845. Epub 2019 May 9.
5
Early and late hematologic toxicity following CD19 CAR-T cells.CD19嵌合抗原受体T细胞治疗后的早期和晚期血液学毒性
Bone Marrow Transplant. 2019 Oct;54(10):1643-1650. doi: 10.1038/s41409-019-0487-3. Epub 2019 Feb 26.
6
Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ.艾曲波帕在由 IFN-γ 介导的炎症条件下维持人造血干细胞和祖细胞。
Blood. 2019 May 9;133(19):2043-2055. doi: 10.1182/blood-2018-11-884486. Epub 2019 Feb 25.
7
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.阿基仑赛注射液治疗难治性大 B 细胞淋巴瘤的长期安全性和疗效（ZUMA-1）：一项单臂、多中心、1-2 期临床试验。
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
8
Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia.重型再生障碍性贫血治疗后血浆血小板生成素水平持续升高。
Exp Hematol. 2018 Feb;58:39-43. doi: 10.1016/j.exphem.2017.09.006. Epub 2017 Sep 20.
9
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.艾曲波帕治疗慢性免疫性血小板减少症（RAISE）：6 个月随机、3 期研究。
Lancet. 2011 Jan 29;377(9763):393-402. doi: 10.1016/S0140-6736(10)60959-2. Epub 2010 Aug 23.
10
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.艾曲泊帕对慢性特发性血小板减少性紫癜治疗期间血小板计数及出血情况的影响：一项随机、双盲、安慰剂对照试验
Lancet. 2009 Feb 21;373(9664):641-8. doi: 10.1016/S0140-6736(09)60402-5.